ENTREP3: A Potential Drug Target and Biomarker (G10712)

Target Name: ENTREP3

NCBI ID: G10712

ENTREP3

ENTREP3: A Potential Drug Target and Biomarker

ENTREP3, also known as protein ENTREP3, is a protein that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. ENTREP3 is a member of the ENTREP family, which includes several related proteins that have been shown to play important roles in various physiological processes, including insulin sensitivity, inflammation, and cell signaling.

The ENTREP3 protein is a transmembrane protein that is expressed in various tissues and organs, including the brain, pancreas, heart, and blood vessels. It is characterized by a long extracellular domain that is involved in several key signaling pathways, including the TGF-β pathway, the PI3K/Akt pathway, and the NF-kappa-B pathway.

One of the most significant functions of ENTREP3 is its role in insulin sensitivity. Insulin sensitivity is a critical factor in the development and progression of type 2 diabetes, andENTREP3 has been shown to play a key role in regulating insulin sensitivity. Several studies have shown that ENTREP3 can improve insulin sensitivity in animal models of type 2 diabetes, and these effects are associated with changes in the expression and activity of ENTREP3.

In addition to its role in insulin sensitivity, ENTREP3 is also involved in several other biological processes that are relevant to its potential drug target and biomarker status. For example, ENTREP3 has been shown to play a key role in inflammation, with several studies showing that it is involved in the regulation of immune cell function and the production of pro-inflammatory cytokines.

ENTREP3 has also been shown to be involved in cell signaling, with several studies showing that it can interact with several different signaling pathways, including the TGF-β pathway, the PI3K/Akt pathway, and the NF-kappa-B pathway. These interactions suggest that ENTREP3 may be involved in the regulation of cellular processes that are important for human health and disease, including the regulation of inflammation, cell growth, and survival.

Given its involvement in several key biological processes, ENTREP3 is a promising candidate for drug targeting and biomarker development. Several studies have shown that ENTREP3 can be targeted by small molecules, including inhibitors of the TGF-β pathway and the PI3K/Akt pathway. In addition, several studies have shown that ENTREP3 is involved in several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. These findings suggest that ENTREP3 may be a useful drug target and biomarker for a variety of diseases.

While more research is needed to fully understand the role of ENTREP3 in disease, its potential as a drug target and biomarker is an exciting area of research. Further studies are needed to determine the exact mechanisms of ENTREP3's biology and to explore its potential as a drug target and biomarker.

Protein Name: Endosomal Transmembrane Epsin Interactor 3

The "ENTREP3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ENTREP3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets